Stay updated on ARV-471 & Palbociclib in ER+/HER2- mBC Clinical Trial
Sign up to get notified when there's something new on the ARV-471 & Palbociclib in ER+/HER2- mBC Clinical Trial page.

Latest updates to the ARV-471 & Palbociclib in ER+/HER2- mBC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedUpdated study details add a core biopsy requirement for ER IHC and PD testing, and introduce dose escalation with an RP2D plus a palbociclib combination cohort. ARV-471 dosing for Parts A and B is now specified as QD or BID for 28-day cycles, with pharmacokinetic endpoints (AUC) included.SummaryDifference0.8%

- Check21 days agoChange DetectedAdded a government funding lapse notice indicating NIH Clinical Center status and updated the system revision from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check28 days agoChange DetectedThe page now shows the glossary and new metadata fields (Last Update Submitted that Met QC Criteria, Last Update Posted, No FEAR Act Data) with revision updated to v3.4.0; older metadata fields and the previous revision v3.3.4 were removed.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision: v3.3.4 was added and Revision: v3.3.3 was removed.SummaryDifference0.0%

- Check63 days agoChange DetectedThe page now includes a consolidated Locations section listing California, Connecticut, Florida, Illinois, Massachusetts, Michigan, Missouri, New Jersey, New York, North Carolina, Tennessee, and Washington, with a new revision tag v3.3.3. The previous state-specific location sections and the HHS Vulnerability Disclosure link have been removed, and the Revision tag changed from v3.3.2.SummaryDifference1%

- Check92 days agoChange DetectedAdded a new Revision: v3.3.2 and removed Revision: v3.2.0 in the page's release notes area.SummaryDifference0.0%

Stay in the know with updates to ARV-471 & Palbociclib in ER+/HER2- mBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ARV-471 & Palbociclib in ER+/HER2- mBC Clinical Trial page.